LivaNova (LIVN) Earning Somewhat Favorable Media Coverage, Analysis Shows

News stories about LivaNova (NASDAQ:LIVN) have been trending somewhat positive on Thursday, Accern reports. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. LivaNova earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.5852678354691 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

LivaNova (NASDAQ LIVN) opened at $83.31 on Thursday. The firm has a market capitalization of $3,989.99, a P/E ratio of 71.21, a PEG ratio of 2.46 and a beta of 0.83. The company has a current ratio of 2.03, a quick ratio of 1.42 and a debt-to-equity ratio of 0.04. LivaNova has a 12-month low of $45.67 and a 12-month high of $88.56.

A number of analysts have issued reports on the company. BidaskClub raised LivaNova from a “hold” rating to a “buy” rating in a research note on Friday, January 26th. Zacks Investment Research downgraded LivaNova from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 25th. ValuEngine raised LivaNova from a “hold” rating to a “buy” rating in a research note on Friday, February 2nd. Needham & Company LLC lifted their price objective on LivaNova to $93.00 and gave the stock a “buy” rating in a research note on Tuesday, November 21st. Finally, Canaccord Genuity reissued a “hold” rating and set a $76.00 target price on shares of LivaNova in a research report on Tuesday, December 5th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company. LivaNova has a consensus rating of “Hold” and an average price target of $79.71.

In other news, Director Daniel Jeffrey Moore sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $81.39, for a total transaction of $81,390.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Hugh M. Morrison sold 1,830 shares of the business’s stock in a transaction that occurred on Wednesday, November 29th. The shares were sold at an average price of $88.00, for a total value of $161,040.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 6,830 shares of company stock worth $576,920. Corporate insiders own 0.28% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This article was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at

LivaNova Company Profile

LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.

Insider Buying and Selling by Quarter for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit